Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2019-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Samsung Pharm Co., Ltd. for the period of January 1, 2019, to March 31, 2019. It contains detailed financial statements, business descriptions, capital changes, and management information. This document is a comprehensive financial report for a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-15 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory disclosure from Samsung Pharmaceutical regarding the acquisition of shares in another company (Korea Stem Cell Bank). It details the acquisition amount, purpose, and board approval, which is a standard corporate action announcement. Since it does not fit into specific categories like M&A (which usually implies a merger or takeover of the entity itself) or share issuance, and it is a specific regulatory disclosure of a material event, it falls under the 'Regulatory Filings' (RNS) category as the most appropriate fallback for miscellaneous corporate announcements.
2019-04-23 Korean
신규시설투자등
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding a new facility investment (capital expenditure). It details the investment amount, purpose (production line for a pancreatic cancer drug), and timeline. Since this is a specific corporate announcement regarding capital allocation and facility expansion that does not fit into the other specific categories like M&A or share issues, it is classified as a general regulatory filing.
2019-04-17 Korean
사업보고서 (2018.12)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Samsung Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2018. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This document constitutes a comprehensive annual financial report for the company, which falls under the 'Interim / Quarterly Report' (IR) category in the provided schema, as it contains substantive financial statements and analysis for a specific period. FY 2018
2019-04-01 Korean
정기주주총회결과(제65기)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the voting outcomes for various agenda items (financial statements, director/auditor compensation, etc.) from the 65th Annual General Meeting of Samsung Pharmaceutical. Since it reports the official results of shareholder votes at a general meeting, it falls under the 'Declaration of Voting Results & Voting Rights Announcements' category.
2019-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing from Samsung Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, revenue, profit/loss) for both consolidated and separate financial statements for the fiscal year ending 2018. While it contains financial data, it is a formal notification of the audit report's completion and submission to the regulator, rather than the full 10-K annual report itself. Under the 'Menu vs Meal' rule, this is a report publication announcement regarding the audit results. FY 2018
2019-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.